Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
- Resource Type
- Article
- Source
- In
Clinical Genitourinary Cancer September 2013 11(3):270-275 - Subject
- Language
- ISSN
- 1558-7673